CERo Therapeutics Holdings, Inc.
CERO
$9.46
$0.232.49%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.46M | 11.14M | 10.03M | 7.66M | 6.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.75M | 16.20M | 15.22M | 12.36M | 9.62M |
| Operating Income | -16.75M | -16.20M | -15.22M | -12.36M | -9.62M |
| Income Before Tax | -11.11M | -8.30M | -10.24M | -7.36M | -7.01M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.11 | -8.30 | -10.24 | -7.36 | -7.01 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.11M | -8.30M | -10.24M | -7.36M | -7.01M |
| EBIT | -16.75M | -16.20M | -15.22M | -12.36M | -9.62M |
| EBITDA | -16.35M | -15.76M | -14.77M | -11.90M | -9.16M |
| EPS Basic | -311.64 | -342.01 | -306.30 | -153.81 | -116.26 |
| Normalized Basic EPS | -159.43 | -182.20 | -154.03 | -42.32 | -42.32 |
| EPS Diluted | -311.64 | -342.01 | -306.30 | -153.81 | -116.26 |
| Normalized Diluted EPS | -159.43 | -182.20 | -154.03 | -42.32 | -42.32 |
| Average Basic Shares Outstanding | 5.43M | 1.86M | 559.50K | 37.90K | 37.90K |
| Average Diluted Shares Outstanding | 5.46M | 1.90M | 597.40K | 296.60K | 479.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |